Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer

American Journal of Pathology

Volumn 178, Issue 2, 2011, Pages 861-871

  Mannelqvist, Monica ^a,b   Stefansson, Ingunn M ^a,b   Bredholt, Geir ^a   Bø, Trond Hellem ^a   Øyan, Anne M ^a,b   Jonassen, Inge ^a   Kalland, Karl Henning ^a,b   Salvesen, Helga B ^a,b   Akslen, Lars A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1 FAMILY MEMBER A2; ANGIOPOIETIN LIKE 4; ATAXIA CEREBELLAR CAYMAN TYPE PROTEIN; CHROMOSOME 1 OPEN READING FRAME 114 PROTEIN; COLLAGEN TYPE 4; COLLAGEN TYPE 4 ALPHA 6; COLLAGEN TYPE 8; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FORMYL PEPTIDE RECEPTOR 2; GENE PRODUCT; INTER ALPHA(GLOBULIN)INHIBITOR H5; INTERLEUKIN 8; KELCH LIKE 13 PROTEIN; MAM DOMAIN CONTAINING 2 PROTEIN; NERVE CELL ADHESION MOLECULE; ODD SKIPPED RELATED 2 PROTEIN; OSTEOGLYCIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; SEMA5A PROTEIN; SERPIN PEPTIDASE INHIBITOR; STROMELYSIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; ENDOMETRIUM CARCINOMA; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; VASCULAR INVASION; WESTERN BLOTTING; WOUND HEALING;

EID: 79951827548     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.10.040     Document Type: Article

References (53)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70 (Pubitemid 30046295)
2. Ferrari MK, McNeal JE, Malhotra SM, Brooks JD: Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables. Urology 2004, 64:749-753 (Pubitemid 39446056)
3. Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO: Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007, 31:1825-1833 (Pubitemid 350175809)
4. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA: Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004, 44:472-479 (Pubitemid 38725676)
5. Straume O, Akslen LA: Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 1996, 78:1211-1219 (Pubitemid 26303886)
6. Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer 1997, 80:1529-1537 (Pubitemid 27444024)
7. Mannelqvist M, Stefansson I, Salvesen HB, Akslen LA: Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology 2009, 54:174-183
8. Stefansson IM, Salvesen HB, Akslen LA: Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 2006, 66:3303-3309
9. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536
10. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009, 106:4834-4839
11. Halvorsen OJ, Oyan AM, Bø TH, Olsen S, Rostad K, Haukaas SA, Bakke AM, Marzolf B, Dimitrov K, Stordrange L, Lin B, Jonassen I, Hood L, Akslen LA, Kalland KH: Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. Int J Oncol 2005, 26:329-336
12. Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bo TH, Stordrange L, Olsen S, Haukaas SA, Lin B, Hood L, Jonassen I, Akslen LA, Kalland KH: ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 2007, 30:19-32
13. Øyan AM, Anensen N, Bø TH, Stordrange L, Jonassen I, Bruserud Ø, Kalland KH, Gjertsen BT: Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 2009, 9:77
14. Dysvik B, Jonassen I: J-Express: exploring gene expression data using Java. Bioinformatics 2001, 17:369-370 (Pubitemid 32421932)
15. Yang YH, Buckley MJ, Speed TP: Analysis of cDNA microarray images. Brief Bioinform 2001, 2:341-349
16. Bø TH, Dysvik B, Jonassen I: LSimpute: accurate estimation of missing values in microarray data with least squares methods. Nucleic Acids Res 2004, 32:e34
17. Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, Øyan AM, Otte AP, Kalland KH, Akslen LA, Salvesen HB: Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer 2008, 98:1662-1669 (Pubitemid 351684686)
18. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response [Erratum appeared in Proc Natl Acad Sci U S A 2001, 98:10515]. Proc Natl Acad Sci USA 2001, 98:5116-5121
19. Leblond CP, Inoue S: Structure, composition, and assembly of basement membrane. Am J Anat 1989, 185:367-390 (Pubitemid 19213501)
20. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, Lazareva-Ulitsky B: Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 2006, 34:W645-W650 (Pubitemid 44529850)
21. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550 (Pubitemid 41528093)
22. Guyon I, Elisseeff A: An introduction to variable and feature selection. J Mach Learn Res 2003, 3:1157-1182
23. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO: Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7
24. Ho M, Yang E, Matcuk G, Deng D, Sampas N, Tsalenko A, Tabibiazar R, Zhang Y, Chen M, Talbi S, Ho YD, Wang J, Tsao PS, Ben-Dor A, Yakhini Z, Bruhn L, Quertermous T: Identification of endothelial cell genes by combined database mining and microarray analysis. Physiol Genomics 2003, 13:249-262 (Pubitemid 37129190)
25. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77 (Pubitemid 351442989)
26. Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM: A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 2009, 7:9
27. Stefansson IM, Salvesen HB, Akslen LA: Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004, 22:1242-1252 (Pubitemid 41079838)
28. Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2:811-814 (Pubitemid 26225099)
29. Bachmann IM, Puntervoll HE, Otte AP, Akslen LA: Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 2008, 21:583-590 (Pubitemid 351589652)
30. Hanson MB, van Nagell JR, Powell DE, Donaldson ES, Gallion H, Merhige M, Pavlik EJ: The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 1985, 55:1753-1757 (Pubitemid 15103925)
31. Sivridis E, Buckley CH, Fox H: The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br J Obstet Gynaecol 1987, 94:991-994 (Pubitemid 18067132)
32. Gal D, Recio FO, Zamurovic D, Tancer ML: Lymphovascular space involvement-a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol 1991, 42:142-145
33. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P, Monnot C, Germain S: Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006, 103:18721-18726 (Pubitemid 44913477)
34. Nelson CM, Khauv D, Bissell MJ, Radisky DC: Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. J Cell Biochem 2008, 105:25-33
35. Sibinga NE, Foster LC, Hsieh CM, Perrella MA, Lee WS, Endege WO, Sage EH, Lee ME, Haber E: Collagen VIII is expressed by vascular smooth muscle cells in response to vascular injury. Circ Res 1997, 80:532-541 (Pubitemid 27137290)
36. Przybylo JA, Radisky DC: Matrix metalloproteinase-induced epithelial- mesenchymal transition: tumor progression at Snail's pace. Int J Biochem Cell Biol 2007, 39:1082-1088 (Pubitemid 46819134)
37. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ: Rac1b and reactive oxygen species mediate MMP-3 -induced EMT and genomic instability. Nature 2005, 436:123-127 (Pubitemid 40966197)
38. Nö E V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001, 114:111-118 (Pubitemid 32120080)
39. Lochter A, Srebrow A, Sympson CJ, Terracio N, Werb Z, Bissell MJ: Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J Biol Chem 1997, 272:5007-5015 (Pubitemid 27090053)
40. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997, 139:1861-1872 (Pubitemid 28079248)
41. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z: The stromal proteinase MMP3/stromelysin- 1 promotes mammary carcinogenesis. Cell 1999, 98:137-146 (Pubitemid 29344902)
42. Huang Y, Song N, Ding Y, Yuan S, Li X, Cai H, Shi H, Luo Y: Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 2009, 69:7529-7537
43. Welm AL: TGFbeta primes breast tumor cells for metastasis. Cell 2008, 133:27-28
44. Le Jan S, Amy C, Cazes A, Monnot C, Lamandé N, Favier J, Philippe J, Sibony M, Gasc JM, Corvol P, Germain S: Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003, 162:1521-1528 (Pubitemid 36512834)
45. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ, Riggins GJ: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001, 93:1337-1343 (Pubitemid 32910575)
46. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J: Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524 (Pubitemid 41112921)
47. Paulus W, Sage EH, Liszka U, Iruela-Arispe ML, Jellinger K: Increased levels of type VIII collagen in human brain tumours compared to normal brain tissue and non-neoplastic cerebral disorders. Br J Cancer 1991, 63:367-371
48. Muragaki Y, Mattei MG, Yamaguchi N, Olsen BR, Ninomiya Y: The complete primary structure of the human alpha 1 (VIII) chain and assignment of its gene (COL8A1) to chromosome 3. Eur J Biochem 1991, 197:615-622
49. MacBeath JR, Kielty CM, Shuttleworth CA: Type VIII collagen is a product of vascular smooth-muscle cells in development and disease. Biochem J 1996, 319:993-998 (Pubitemid 26386219)
50. Bendeck MP, Regenass S, Tom WD, Giachelli CM, Schwartz SM, Hart C, Reidy MA: Differential expression of alpha 1 type VIII collagen in injured platelet-derived growth factor-BB-stimulated rat carotid arteries. Circ Res 1996, 79:524-531 (Pubitemid 26276912)
51. Hou G, Mulholland D, Gronska MA, Bendeck MP: Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury. Am J Pathol 2000, 156:467-476 (Pubitemid 30643802)
52. Adiguzel E, Hou G, Mulholland D, Hopfer U, Fukai N, Olsen B, Bendeck M: Migration and growth are attenuated in vascular smooth muscle cells with type VIII collagen-null alleles. Arterioscler Thromb Vasc Biol 2006, 26:56-61 (Pubitemid 43732228)
53. Aggarwal BB, Gehlot P: Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol 2009, 9:351-369